[NewsPrime] C&R Research signed a contract with Trutino Biosciences to conduct a Phase 1b clinical trial for an immuno-oncology drug candidate
C&R Research signed a contract to conduct a Phase 1b clinical trial for an immuno-oncology drug candidate, commissioned by Trutino Biosciences, a San Diego based biotechnology company.
This is a visible achievement since the establishment of C&R Research’s U.S. subsidiary in Boston last November. It marks an important step in expanding the market by identifying clients in the U.S. and conducting the clinical trial domestically in South Korea.
The Phase 1b clinical trial represents the first human study for the development of an innovative immuno-oncology treatment based on Trutino Biosciences’ “On-Demand Cytokine (ODC)” platform. The trial aims to evaluate the safety and early efficacy of the immuno-oncology drug candidate.
We are pleased to collaborate with global biotech company Trutino Biosciences. We will continue to make every effort to meet the needs of our diverse domestic and international clients by conducting top-tier clinical trials.
Please check out further details by following the link below.
